PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
Patients will receive RCD or PCD combination as induction treatment followed by rituximab or velcade maintenance therapy, as the investigators try to compare the, very good partial remission (VGPR) rate, complete remission (CR) rates, Overall remission rate (MR+CR + VGPR + partial remission (PR) rate), major reaction rate (MRR, PR+VGPR+CR) at the end of the research.
Epistemonikos ID: ae24c908c44d1eb107bf326d0026ba06965cdf05
First added on: May 20, 2024